Philip Tønnesen

TL;DR: In this paper, a randomized controlled trial was conducted to determine whether smokers who quit after 12 weeks of treatment with varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, maintain greater continuous abstinence rates (defined as not a single “puff” of a cigarette) than placebo controls.

TL;DR: CT screening for lung cancer brings forward early disease, and at this point no stage shift or reduction in mortality was observed, indicating some degree of over diagnosis and need for longer follow-up.

TL;DR: The nicotine skin patch proved to be safe and effective, as demonstrated by a higher rate of abstinence than with placebo, which is lower than the rate in studies that have combined the use of nicotine chewing gum with behavioral therapy.

TL;DR: Older participants, those with chronic obstructive pulmonary disease, and those with more than 35 pack-years of smoking had a significantly increased risk of death due to lung cancer, with nonsignificantly fewer deaths in the screening group.

TL;DR: A higher than standard dose of nicotine patch was associated with an increase in the long-term success in smoking cessation but continuation of treatment beyond 8-12 weeks did not increase the success rates.